The short version of growth hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-09. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
== Habitat and ecology == Aspergillus parasiticus can be found outdoors commonly within an agricultural setting of soil on fields and through the improper handling, drying, transportation and storage of grains and fresh produce. This fungus is also commonly found on the stems and roots of peanuts and other plants. A. parasiticus is a tropical and subtropical species found in the United States, Latin America, South Africa, India and Australia. This species has rarely been reported from Southeast Asia and cool temperate zones. Fungal spores can be distributed with the wind as well as through moist soil via contact with nuts and kernels, and can survive over the winter months on plant material on the soil.
=== Aspartate === The biosynthesis of aspartate frequently involves the transamination of oxaloacetate. The enzyme aspartokinase, which catalyzes the phosphorylation of aspartate and initiates its conversion into other amino acids, can be broken up into 3 isozymes, AK-I, II and III. AK-I is feed-back inhibited by threonine, while AK-II and III are inhibited by lysine. As a sidenote, AK-III catalyzes the phosphorylation of aspartic acid that is the committed step in this biosynthetic pathway. Aspartate kinase becomes downregulated by the presence of threonine or lysine.
{\displaystyle {\begin{aligned}R_{*}&={\frac {\varepsilon }{D}}\cdot \mathrm {Re} {\sqrt {f_{\mathrm {D} }}}\cdot {\frac {1}{\sqrt {8}}}\\&={\frac {1}{2}}{\frac {\sqrt {g}}{\nu }}\varepsilon {\sqrt {S}}{\sqrt {D}}\end{aligned}}}
The International History Review. 30 (4): 709–740. doi:10.1080/07075332.2008.10416646. ISSN 1949-6540. JSTOR 40213728. S2CID 153677447. Panzac, Daniel (1995). Histoire économique et sociale de l'Empire ottoman et de la Turquie (1326-1960). Peeters Publishers. ISBN 90-6831-799-7. Pappé, Ilan (2006). The Ethnic Cleansing of Palestine. Oneworld. ISBN 978-1-85168-555-4. Reilly, James A. (2016). The Ottoman Cities of Lebanon: Historical Legacy and Identity in the Modern Middle East. London: I. B. Tauris. ISBN 978-1-78672-036-8. Salibi, Kamal S. (January 1961). "The Buḥturids of the Garb. Mediaeval Lords of Beirut and of Southern Lebanon". Arabica. 8 (1): 74–97. doi:10.1163/157005861X00043. JSTOR 4054971. Salibi, K. (1965). "Fakhr al-Dīn". In Lewis, B.; Pellat, Ch. & Schacht, J. (eds.). The Encyclopaedia of Islam, Second Edition. Volume II: C–G. Leiden: E. J. Brill. pp. 749–751. OCLC 495469475. Salibi, K. (February 1968). "The muqaddams of Bšarrī: Maronite chieftains of the Northern Lebanon 1382–1621". Arabica. 15 (1): 63–86. doi:10.1163/157005868X00280. ISSN 0570-5398. JSTOR 4056124. Salibi, K. (2005). A House of Many Mansions: The History of Lebanon Reconsidered. London: I.B. Tauris. ISBN 978-1-86064-912-7. Salibi, Kamal Suleiman (2005b). The Druze: Realities & Perceptions. University of Michigan Press. ISBN 978-1-904850-06-9. Schilcher, L. Schatkowski (1981). "The Hauran Conflicts of the 1860s: A Chapter in the Rural History of Modern Syria". International Journal of Middle East Studies. 13 (2): 159–179. doi:10.1017/S0020743800055276. JSTOR 162818. S2CID 162263141.
Sources: en.wikipedia.org
=== World War I === In World War I, the US Navy contracted for 18 refrigerated ships for hauling provisions to the troops in Europe. They were launched 1918 and 1919 as the war was ending and were nearly all scrapped by 1933 in the Great Depression as an economy move. Most were built in Baltimore Dry Dock in Baltimore, Maryland, Moore Dry Dock Company in Oakland, California, and Standard SB Co. in Shooters Island, New York.
=== Identification, theories, and investigation === An unidentified object was reported at the top of the tower on October 8, and it became famous. Gould Colman, who had just retired as the university's archivist, stated that the occurrence was "much better than a prank," and "first-rate stuff, the best that I've seen. What a clever accomplishment to get this pumpkin up there." Students placed a collection of pumpkins at the base of the tower, before the university placed an orange fence around the tower with a sign stating "Beware of Falling Pumpkin". A website for the pumpkin was created which was viewed 700,000 times, and featured a dedicated online webcam feed. A student wrote a pumpkin version of the Cornell song. For three weeks, the pumpkin was the subject of a daily feature in The Cornell Daily Sun called "Pumpkin Watch" on its front page, as well as coverage from Associated Press and MTV. While it was largely thought to be a pumpkin, some at the university doubted this assessment, with one assistant professor of horticultural sciences stating that it was too hardy to be of biotic origin. In an effort to definitively identify the object, the university sponsored a contest to identify it without leaving the ground. Physics and engineering students used remote controlled weather balloons, including one with a hypodermic needle to take samples and another with a drill and video cameras, in attempts to identify it. The contest had five entrants, two teams and three individuals.
==== Other ==== The use of statins in diabetes to prevent cardiovascular disease should be considered after evaluating the person's total risk for cardiovascular disease. The use of aspirin (acetylsalicylic acid) to prevent cardiovascular disease in diabetes is controversial. Aspirin is recommended in people with previous cardiovascular disease, however routine use of aspirin has not been found to improve outcomes in uncomplicated diabetes. Aspirin as primary prevention may have greater risk than benefit, but could be considered in people aged 50 to 70 with another significant cardiovascular risk factor and low risk of bleeding after information about possible risks and benefits as part of shared-decision making. Vitamin D supplementation to people with type 2 diabetes may improve markers of insulin resistance and HbA1c. Sharing their electronic health records with people who have type 2 diabetes helps them to reduce their blood sugar levels. It is a way of helping people understand their own health condition and involving them actively in its management.
== Bibliography == Cécile Allegri, Claire Brosse, Federico Oldenburg and Hervé Robert, La Pomme de terre, saveurs méditerranéennes, Éditions du Bottin Gourmand, coll. « Les essentiels du goût », 2003, 99 p. (ISBN 2-913306-61-6). Joseph Bonjean, Monographie de la pomme de terre envisagée dans ses rapports agricoles, scientifiques et industriels et comprenant l'histoire générale de la maladie des pommes de terre en 1845, Paris, Germer Baillière, 1846, 306 p. Collective, La Pomme de terre. Histoire et recettes gourmandes, Grenoble, Glénat, 2009, 160 p. (ISBN 2-7234-7319-8). Collective, La Pomme de terre, un tour du Monde en 200 recettes, Geneva, United Nations, 2008, 360 p. (ISBN 92-1-200373-7). Lucienne Desnoues, Toute la pomme de terre, Paris, Mercure de France, 1978, 302 p. Qu Dongyu et Xie Kaiyun, How the Chinese Eat Potatoes, Singapour, World Scientific Publishing Company, 2009, 432 p. (ISBN 981-283-291-2). Jean Ferniot (pref. Joël Robuchon), Chère pomme de terre, First, 1996, 301 p. (ISBN 978-2-87691-327-1). Martine Jolly, Merci M. Parmentier, ou La gloire de la pomme de terre en 200 recettes, Robert Laffont, 1985, 224 p. (ISBN 2-221-04653-6). Mme Mérigot, La Cuisinière républicaine, qui enseigne la manière simple d'accommoder les pommes de terre; avec quelques avis sur les soins nécessaires pour les conserver Archived July 12, 2023, at the Wayback Machine, Paris, Chez Mérigot jeune, 1794–1795, 42 p. C. Monteros, J. Jiménez, Gavilanes, La Magia de la Papa Nativa. Recetario Gastronómico, Quito, INIAP, 2006, 71 p.
The island chain is a western continuation of the Aleutian Range on the mainland. The great majority of the islands bear evident marks of volcanic origin, and there are numerous volcanic cones on the north side of the chain, some of them active; many of the islands, however, are not wholly volcanic, but contain crystalline or sedimentary rocks, and also amber and beds of lignite. The coasts are rocky and surf-worn, and the approaches are exceedingly dangerous, the land rising immediately from the coasts to steep, bold mountains. These volcanic islands reach heights of 6,200 feet (1,900 m). Makushin Volcano (5,691 feet (1,735 m)) on Unalaska Island, is not quite visible from within the town of Unalaska, though the steam rising from its cone is visible on a (rare) clear day. Residents of Unalaska need only to climb one of the smaller hills in the area, such as Pyramid Peak or Mt. Newhall, to get a good look at the snow-covered cone. The volcanic Bogoslof and Fire Islands, which rose from the sea in 1796 and 1883 respectively, lie about 30 miles (50 km) west of Unalaska Bay. In 1906, a new volcanic cone rose between the islets of Bogoslof and Grewingk, near Unalaska, followed by another in 1907. These cones were nearly demolished by an explosive eruption on September 1, 1907. In 2017, the volcanic cone erupted sending ash and ice particles 30,000 feet (9000 m) into the air.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.